Renovaro Inc. Changes Name to Lunai Bioworks, Focusing on AI-Driven Biodefense and Drug Discovery.

Renovaro Inc. is changing its name to Lunai Bioworks, Inc. to reflect its focus on AI-driven biodefense, drug discovery, and advanced diagnostics. The company is enhancing collaboration across its teams and aligning resources for growth, with a strong North American base and partnerships with leading biopharmaceutical companies. Lunai Bioworks is pioneering a new era of precision diagnostics using multimodal AI to decode complex biological signals in real time, with a focus on early detection, patient stratification, and therapeutic targeting.

Title: Renovaro Inc. Renames to Lunai Bioworks, Inc. to Reflect AI-Driven Biodefense and Drug Discovery Focus

Renovaro Inc. (NASDAQ: RENB) has announced a significant corporate rebranding, changing its name to Lunai Bioworks, Inc. This strategic move underscores the company's commitment to leveraging artificial intelligence (AI) in biodefense, drug discovery, and advanced diagnostics. The new name, Lunai Bioworks, reflects the company's focus on integrating advanced computational biology and AI/machine learning to accelerate drug discovery and diagnostics, while strengthening biosecurity capabilities.

The rebranding coincides with the company's merger with BioSymetrics, which brought established partnerships with major pharmaceutical companies including Janssen, Pfizer, Merck, Supernus Pharma, and Deerfield Cures. These partnerships have validated Lunai's proprietary platforms in translational analytics, in vivo modeling, and machine vision, accelerating biomarker discovery and therapeutic development in precision neurology and infectious disease.

Lunai's diagnostic capabilities extend beyond traditional boundaries, leveraging multimodal AI to decode complex biological signals in real time. From high-resolution phenotyping to predictive disease modeling, the company is pioneering a new era of precision diagnostics, where early detection, patient stratification, and therapeutic targeting converge into a single, adaptive platform. These innovations aim to transform clinical decision-making, reduce time-to-treatment, and unlock previously inaccessible insights from biological data.

"Our new name, Lunai Bioworks, captures the fusion of intelligence, innovation, and mission that drives us forward," said David Weinstein, CEO of the Company. "By uniting our teams and focusing squarely on AI-driven biodefense and drug discovery, we are building a platform that can deliver breakthrough solutions for some of the world's most pressing health and security challenges."

The name change was approved by the Board of Directors, and the company's common stock will continue to trade on Nasdaq under its current ticker symbol, RENB, until further notice.

Lunai's strategic pivot positions it at the intersection of three rapidly growing markets: the biodefense sector, AI-accelerated drug discovery, and precision diagnostics. This alignment with current biotechnology trends could enhance its competitive positioning, particularly if it can successfully integrate the computational strengths from BioSymetrics with its existing biological expertise.

References:
1. [1] https://www.stocktitan.net/news/RENB/renovaro-inc-announces-corporate-name-change-to-lunai-bioworks-inc-uajx2rh25mjk.html
2. [2] https://www.ainvest.com/news/photronics-navigating-semiconductor-downturn-strategic-precision-ai-driven-growth-2508/